Cancer-Associated thrombosis: An update from the SELECT-D pilot study

In this video (filmed in June 2018), Professor Annie Young provides an overview of the Transitioning NVAF Patients rationale, design and efficacy and safety outcomes from the SELECT-D pilot study, comparing rivaroxaban with dalteparin for the secondary prevention of VTE in cancer patients.

This webinar was recorded in June 2018. This was a promotional webinar intended for UK Healthcare Professionals that was organised and fully funded by Bayer plc.

We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.

To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget

Reporting adverse events and quality complaints

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email:

Further information is available on the "contact" tab at